Sphere Medical successfully completes Initial Public Offering

For further information:  QUEST MANAGEMENT NV  
Mr. René Avonts, Managing Director  
Tel: +32 (0)16 28 41 28  
Fax: +32 (0)16 28 41 29

QUEST MANAGEMENT NV  
Ms. Els Hubloux, Senior Investment Manager  
Tel: +32 (0)16 28 41 28  
Fax: +32 (0)16 28 41 29

Sphere Medical, one of Quest for Growth’s portfolio companies, raises £ 14 million in an IPO and started trading on AIM earlier today.

The company issued 15,135,135 new shares priced at 92,5 pence per share. The company’s enlarged issued share capital is 36,805,644, valuing the company at £ 34 million. Peel Hunt acted as nominated adviser and broker to Sphere Medical.

Following the IPO Quest for Growth will, in accordance with its valuation rules, apply a 9% discount to the stock price in its books. From the first month following the IPO, the discount applied will decrease by 1.5% per month and will have disappeared completely after 6 months soft lock-up. Quest for Growth meets hereby for that matter her legal investment requirements.

About SPHERE MEDICAL  
www.spheremedical.com

Sphere Medical Holding plc is developing highly innovative monitoring products to provide clinical and economic benefits in the critical care environment, based on the company’s proprietary technology. The products allow minimally invasive, real time measurement of clinical chemistry parameters and therapeutic drug concentrations, giving healthcare professionals the information they require to more effectively manage therapy and optimise patient outcomes. Sphere Medical and the leading clinicians with whom Sphere Medical works believe that its novel technology will enable a major improvement in monitoring practice - and thereby in the standard of patient care - in a range of situations including intensive and critical care medicine, the operating room, during organ failure, during surgical treatments and anaesthesia and in the effective administration of drugs. Sphere Medical was founded in 2002 and is based in Cambridge, UK.

For further information about Sphere Medical, visit www.spheremedical.com
Press release
Leuven / 17 November 2011

About QUEST FOR GROWTH

Quest for Growth focuses on European technology-based growth companies in a broad range of industrial sectors such as information technology, semiconductors, telecommunications, software, electronics, biotechnology, medical devices, health-care and new materials. Quest for Growth invests in quoted and unquoted companies.

Quest for Growth was the first Privak in Belgium and is an investment company listed on the continuous market of Euronext Brussels.

The Privak, created by Royal Decree of April 18th 1997, is an investment vehicle, specially tailored to provide a suitable framework for investments in private equity and in growth companies.

The Privak “Quest for Growth” is managed by Quest Management NV.

More information is available on www.questforgrowth.com.

This announcement is not an offer to sell or a solicitation of an offer to buy any securities in the above companies in which QUEST FOR GROWTH has invested. This announcement appears solely as a matter of record.

The securities of the companies referred to in this document have not been registered with the United States Securities Act of 1933, and may not be offered or sold in the United States other than pursuant to an effective registration statement or an applicable exemption from registration.

This press release may contain forward-looking statements that involve risk and uncertainty. Although QUEST FOR GROWTH believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, no assurance can be given that such projections will be fulfilled. Any such forward-looking statement must be considered along with knowledge that actual events and results may vary materially from such predictions due to, among other things, political, economic or legal changes in the markets in which the companies in which QUEST FOR GROWTH invests do business or the stock markets in which these companies are listed. Readers are referred to the prospectus, which was issued at the time of the IPO that identifies the important risk factors proper to QUEST FOR GROWTH.